Oncogenic addiction to high 26S proteasome levels
P. Tsvetkov, J. Adler, N. Myers, A. Biran, N. Reuven, Y. Shaul
Abstract
Proteasomes are large intracellular complexes responsible for the degradation of cellular proteins. The altered protein homeostasis of cancer cells results in increased dependency on proteasome function. There are several different proteasome complexes that may be assembled in cells, with the 20S catalytic core common to them all. 20S proteasomes can function in isolation, or as part of larger complexes (26S) with regulatory particles (RP) such as the 19S that is needed for the targeting and processing of ubiquitinated substrates. Proteasome inhibitors target the catalytic barrel (20S) and thus this inhibition does not allow the deconvolution of the distinct roles of 20S vs. 26S proteasomes in cancer progression. We examined the degree of dependency of cancer cells specifically to the level of the 26S proteasome complex. We found that oncogenic transformation of human and mouse immortalized cells with mutant Ras induced a strong increase in the translation of the 26S proteasome subunits, giving rise to high 26S complex levels. We show that depletion of a single subunit of the 19S RP was sufficient to significantly reduce the 26S proteasome level and lower the cellular 26S/20S ratio. We further demonstrate that the accumulated 26S proteasome was essential for the viability of the transformed cells. Moreover, the viability of 20 different cancer cell lines, but not normal human fibroblasts, was severely compromised upon specific 26S proteasome suppression regardless of their p53 status. Suppression of 26S activated the UPR and Caspase-3, which at least partially explains the cell-killing effect. Morphologically, suppression of the 26S proteasome resulted in cytoplasm shrinkage and nuclear deformation. Thus, the tumor cell-specific addiction to high 26S proteasome levels sets the stage for future strategies in cancer therapy.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Expression and DNA methylation of 20S proteasome subunits as prognostic and resistance markers in cancer
Ruba Al‐Abdulla, Simone Venz, … Elke Krüger·Molecular OncologyPeer-reviewed·Aug 27, 2025
- NRF1 and NRF3 complementarily maintain a basal proteasome activity in cancer cells through CPEB3-mediated translational repression
Tsuyoshi Waku, Hiroyuki Katayama, … Akira Kobayashi·Molecular and Cellular BiologyPeer-reviewed·May 4, 2020
- Enhancing c-MYC degradation via 20S proteasome activation induces in vivo anti-tumor efficacy
E. Njomen, T. Lansdell, … J. Tepe·bioRxiv·Aug 24, 2020
- Signature activities of 20S proteasome include degradation of the ubiquitin-tag with the protein under hypoxia
I. Sahu, S. M. Mali, … M. H. Glickman·bioRxiv·Dec 20, 2019
- Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1
Merav D. Shmueli, Yongfeng Tao, … Yifat Merbl·bioRxiv·Oct 16, 2026
- Engineered subtilisin protease degrades active KRAS in cancer cells, leading to differential cell targeting
M.E. Goldstein, Betty Chu, … Thomas R. Fuerst·bioRxiv·Mar 6, 2026